Overview

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

Status:
Not yet recruiting
Trial end date:
2022-09-19
Target enrollment:
Participant gender:
Summary
In this study, the study drug 'NNC0385-0434' will be tested in 3 different tablet formulations. These formulations are being tested for the treatment of hypercholesterolemia (high cholesterol). Participants will only receive 2 of the 3 tablet formulations. The treatments participants get are decided by chance. Participants will receive 1 formulation for 10 days (first treatment period) and the other formulation for 5 days (second treatment period). The study will last up to 96 days. Only men can participate in this clinical study.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S